Grifols reports Q1 adjusted EBITDA of EUR 400M, up 14.2% from last year

Net revenues reached EUR 1.786B, up 7.4% in constant currency. Like-for-like net revenues increased by 10.0% in constant currency. Adjusted EBITDA increased to EUR 400M, up 14.2% in constant currency and +21.7% on a constant currency, like-for-like basis. Nacho Abia, Chief Executive Officer, commented: “Building on our record-setting performances in 2023 and 2024, our first quarter clearly demonstrates continued momentum as we focus on executing our strategic plan. Healthy underlying demand in Biopharma and across all parts of our business, coupled with strong operational execution, positions Grifols (GRFS) for consistent growth throughout 2025. While we continue to monitor evolving macroeconomic and policy developments, the long-established Grifols strategy of being local in our largest markets, where we have established self-sufficient, regional plasma ecosystems with vertically integrated operations, helps to better insulate us from broader marketplace challenges.”